Literature DB >> 22291193

Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection.

Christopher D Paddock1, Lindy Liu, Amy M Denison, Jeanine H Bartlett, Robert C Holman, Marlene Deleon-Carnes, Shannon L Emery, Clifton P Drew, Wun-Ju Shieh, Timothy M Uyeki, Sherif R Zaki.   

Abstract

BACKGROUND: Influenza B virus infection causes rates of hospitalization and influenza-associated pneumonia similar to seasonal influenza A virus infection and accounts for a substantial percentage of all influenza-related hospitalizations and deaths among those aged <18 years; however, the pathogenesis of fatal influenza B virus infection is poorly described.
METHODS: Tissue samples obtained at autopsy from 45 case patients with fatal influenza B virus infection were evaluated by light microscopy and immunohistochemical assays for influenza B virus, various bacterial pathogens, and complement components C4d and C9, to identify the cellular tropism of influenza B virus, characterize concomitant bacterial pneumonia, and describe the spectrum of cardiopulmonary injury.
RESULTS: Viral antigens were localized to ciliated respiratory epithelium and cells of submucosal glands and ducts. Concomitant bacterial pneumonia, caused predominantly by Staphylococcus aureus, was identified in 38% of case patients and occurred with significantly greater frequency in those aged >18 years. Pathologic evidence of myocardial injury was identified in 69% of case patients for whom cardiac tissue samples were available for examination, predominantly in case patients aged <18 years.
CONCLUSIONS: Our findings suggest that bacterial pneumonia and cardiac injury contribute to fatal outcomes after infection with influenza B virus and that the frequency of these manifestations may be age related.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22291193     DOI: 10.1093/infdis/jir861

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  65 in total

1.  Influenza at the beginning of the 21st century.

Authors:  Nahoko Shindo; Sylvie Briand
Journal:  Bull World Health Organ       Date:  2012-04-01       Impact factor: 9.408

Review 2.  Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance.

Authors:  Andrew J Burnham; Tatiana Baranovich; Elena A Govorkova
Journal:  Antiviral Res       Date:  2013-09-04       Impact factor: 5.970

3.  [Lower respiratory tract infection caused by influenza virus A and influenza virus B in Wenzhou, China: a clinical analysis of 366 children].

Authors:  Pei-Pei Zhong; Hai-Lin Zhang; Xiao-Fang Chen; Ya-Feng Liang; Li Lin; Shao-Yan Yang; Jiang-Yin Sheng; Chang-Chong Li
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2016-02

4.  Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y.

Authors:  Andrew J Burnham; Tatiana Baranovich; Bindumadhav M Marathe; Jianling Armstrong; Robert G Webster; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

5.  Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference.

Authors:  Jennifer L McKimm-Breschkin; Shibo Jiang; David S Hui; John H Beigel; Elena A Govorkova; Nelson Lee
Journal:  Antiviral Res       Date:  2017-11-21       Impact factor: 5.970

6.  Characterization of the Localized Immune Response in the Respiratory Tract of Ferrets following Infection with Influenza A and B Viruses.

Authors:  Louise A Carolan; Steve Rockman; Kathryn Borg; Teagan Guarnaccia; Patrick Reading; Jennifer Mosse; Anne Kelso; Ian Barr; Karen L Laurie
Journal:  J Virol       Date:  2015-12-30       Impact factor: 5.103

7.  Evidence for Viral Interference and Cross-reactive Protective Immunity Between Influenza B Virus Lineages.

Authors:  Karen L Laurie; William Horman; Louise A Carolan; Kok Fei Chan; Daniel Layton; Andrew Bean; Dhanasekaran Vijaykrishna; Patrick C Reading; James M McCaw; Ian G Barr
Journal:  J Infect Dis       Date:  2018-01-30       Impact factor: 5.226

8.  IFITM3 protects the heart during influenza virus infection.

Authors:  Adam D Kenney; Temet M McMichael; Alexander Imas; Nicholas M Chesarino; Lizhi Zhang; Lisa E Dorn; Qian Wu; Omar Alfaour; Foued Amari; Min Chen; Ashley Zani; Mahesh Chemudupati; Federica Accornero; Vincenzo Coppola; Murugesan V S Rajaram; Jacob S Yount
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-26       Impact factor: 11.205

9.  High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial.

Authors:  Orly Vardeny; Jacob A Udell; Jacob Joseph; Michael E Farkouh; Adrian F Hernandez; Alison J McGeer; H Keipp Talbot; Deepak L Bhatt; Christopher P Cannon; Shaun G Goodman; Inder Anand; David L DeMets; Jon Temte; Janet Wittes; Kristin Nichol; Clyde W Yancy; J Michael Gaziano; Lawton S Cooper; KyungMann Kim; Scott D Solomon
Journal:  Am Heart J       Date:  2018-05-23       Impact factor: 4.749

10.  Molecular characterization of Staphylococcus aureus and influenza virus coinfections in patients with fatal Pneumonia.

Authors:  Amy M Denison; Marlene Deleon-Carnes; Dianna M Blau; Eric C Shattuck; Linda K McDougal; James K Rasheed; Brandi M Limbago; Sherif R Zaki; Christopher D Paddock
Journal:  J Clin Microbiol       Date:  2013-09-25       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.